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Pituitary adenylate cyclase activating polypeptide (PACAP) is a pleiotropic neuropeptide,
first isolated from hypothalamic extracts, but later shown in peripheral organs, such as
endocrine glands, gastrointestinal system, cardiovascular system, and reproductive organs.
PACAP plays a role in fertility and reproduction. Numerous studies report on the gonadal reg-
ulatory effects of PACAP at hypothalamo-hypophyseal levels. However, the local effects of
PACAP at gonadal levels are also important.The present review summarizes the effects of
PACAP in the ovary. PACAP and its receptors are present in the ovary, and PACAP plays a role
in germ cell migration, meiotic division, follicular development, and atresia. The autocrine-
paracrine hormonal effects seem to play a regulatory role in ovulation, luteinization, and
follicular atrophy. Altogether, PACAP belongs to the ovarian regulatory peptides.
Keywords: PACAP, ovary, oocyte, ovulation, luteinization
INTRODUCTION
Pituitary adenylate cyclase activating polypeptide (PACAP) was
originally isolated from the hypothalamus, and named after its
cAMP increasing effect in pituitary cells (Miyata et al., 1989;
Arimura, 2007). PACAP belongs to the vasoactive intestinal pep-
tide (VIP)/secretin/glucagon peptide family. It occurs in two
amino acid forms: PACAP38 and PACAP27, the longer form is the
predominant peptide in mammals. The receptors of PACAP are
the VPAC1 and VPAC2 receptors, which bind VIP and PACAP with
equal affinity and the specific PAC1 receptor, which binds PACAP
selectively (Miyata et al., 1989; Sherwood et al., 2000; Arimura,
2007; Vaudry et al., 2009; Brubel et al., 2010). After the discov-
ery of PACAP, numerous studies described the regulatory effects
of PACAP at hypothalamo-pituitary levels, affecting the synthesis
and release of several releasing and pituitary hormones. However,
soon after its discovery, it was found that PACAP is, and its recep-
tors are, expressed in the peripheral organs, and high levels of
the peptide were found in the gonads (Arimura et al., 1991). This
immediately drew attention to the peptide playing a central role in
fertility and reproduction, not only at central hormonal, but also
at local levels.
The last two decades in PACAP research have revealed that
PACAP influences fertility and reproduction at several levels. The
present mini-review aims to summarize findings on the effects of
PACAP in the ovary and how PACAP influences female gonadal
functions at the ovarian level.
PACAP IN MAMMALIAN FOLLICULAR DEVELOPMENT
Primordial germ cells (oogonia) migrate from the wall of the yolk
sac to the ovaries during early mammalian development. Ovarian
germ cells then undergo mitosis and develop further into pri-
mary oocytes. Developing oocytes are surrounded by epithelial
cells, which build the ovarian follicles. At first, follicular epithelial
cells are flattened and surround the primary oocytes entering the
first meiotic division. They subsequently are arrested during fetal
development until the female reaches sexual maturity. The first
meiotic division is only completed during the follicular devel-
opment before ovulation in each cycle, and the second meiotic
division is completed only at the time of fertilization, resulting in
the haploid gamete (Sadler, 2012).
A cohort of primordial follicles is activated at the beginning
of the maturation process in cyclic manner. Follicular matu-
ration involves changes in the oocyte, the follicular epithelial
cells, and the surrounding ovarian stroma. Although signifi-
cant inter-species differences exist in the follicular growth and
its regulation, the major steps show basic similarities in mam-
malian species, and in most mammals, the vast majority of fol-
licles undergo apoptosis similarly to humans (Matsuda et al.,
2012). Therefore, we will focus on mammalian findings and only
briefly mention other species. Early follicular development is
independent from gonadotropins, but later follicular growth, ovu-
lation, and luteinization are primarily regulated by the pituitary
gonadotropins follicle-stimulating hormone (FSH) and luteiniz-
ing hormone (LH). However, their actions are also dependent on
other peptidergic and non-peptidergic signaling pathways (May-
erhofer et al., 1997; Bodis et al., 2001; Matsuda et al., 2012).
Accumulating evidence shows that PACAP is one of the regulatory
peptides in the ovary.
ACTIONS OF PACAP ON PRIMORDIAL GERM CELLS
There is evidence for the involvement of PACAP in the prolifer-
ation of primordial germ cells (Pesce et al., 1996). The authors
showed PACAP immunoreactivity in gonadal ridges, mostly on
the germ cell surface. Primordial germ cells intensively prolifer-
ate during their migration to the gonadal ridges and PACAP was
found to stimulate this proliferation process. The peptide binds to
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the germ cells and also to gonadal somatic cells (Pesce et al., 1996).
These observations show that PACAP plays an important role in
reproductive functions from the earliest stage of differentiation
and development.
PACAP IN THE OVARY
In rat ovarian cells, PACAP positive cells were found in the preovu-
latory and ovulatory periods (Gras et al., 1996), with PACAP and
PACAP mRNA positivity in granulosa and cumulus cells. Positivity
was also found in stroma cells and theca cells and even nerve fibers
innervating the ovary showed immunopositivity. These observa-
tions suggest that PACAP is involved in a number of processes
regulated via hormonal as well as neuronal activity during follic-
ular development in the ovary (Gras et al., 1996). Another group
published on the existence of PACAP in the rat ovary the same
year (Scaldaferri et al., 1996).
Pituitary adenylate cyclase activating polypeptide expression in
the corpus luteum of the rat was subsequently shown by Kotani
et al. (1997, 1998). Park et al. (2001) showed that PACAP mRNA
was only expressed in the granulosa but not theca cells. This
expression has a stage-specific regulation by GnRH in rat gran-
ulosa cells. While treatment of preovulatory granulosa cells with
GnRH agonist stimulates PACAP mRNA expression, GnRH ago-
nist treatment alone has no effect but reduces the FSH-induced
PACAP mRNA levels. GnRH antagonist on the other hand had
opposite effects: it inhibited induced PACAP gene expression in
preovulatory cells while stimulating expression in immature gran-
ulosa cells. These results show that GnRH plays an important role
in the regulation of ovarian PACAP expression and that PACAP
expression is differentially regulated during the ovarian cycle (Park
et al., 2001). The LH and FSH control of the PACAP expression
was also confirmed by Lee et al. (1999). The involvement of prog-
esterone receptors have also been shown in LH-induced PACAP
gene expression (Ko et al., 1999). In addition, the gonadotropin-
dependent regulation of PACAP mRNA has been confirmed in
bovine preovulatory follicles (Sayasith et al., 2007). PACAP was
found to be expressed in granulosa cells and its expression was
found to be dependent on protein kinase A. A recent study has
shown that PACAP mRNA expression gradually increases in preg-
nancy in the corpus luteum, suggesting its involvement in the
maintenance of mid-term and late pregnancy (Zhao et al., 2010).
Transient expression of PACAP has also been observed in the
mouse ovary within granulosa cells of preovulatory follicles after
hCG treatment (Barberi et al., 2007). The contemporary induc-
tion of PACAP in preovulatory follicles suggests an important role
for PACAP around the time of ovulation (Barberi et al., 2007).
In human granulosa cells, it has been found that FSH and LH
promote PACAP expression (Morelli et al., 2008). PACAP is syn-
thesized as a preprohormone and is processed by prohormone
convertases. It has been shown that in both testis and ovary, pro-
hormone convertase 4 is the enzyme responsible for PACAP pro-
cessing, supported by the finding that prohormone convertase 4
deficient mice expressed no PACAP in their ovaries (Li et al., 2000).
EXPRESSION OF PACAP RECEPTORS IN THE OVARY
Earlier studies examining binding sites for PACAP have already
identified specific binding sites in the ovary (Gottschall et al.,
1990). Scaldaferri et al. (1996) identified isoforms of the PAC1
receptor in the rat ovary. Later, PAC1 receptors were shown in the
rat corpus luteum (Kotani et al., 1997, 1998). Park et al. (2000)
have demonstrated stage-specific expression of PACAP receptors
in the rat ovary. Northern blot analysis shows that the ovarian tran-
script of the PAC1 receptor appears at day three in the rat ovary,
followed by a gradual increase later in development. There is a
marked increase at puberty, at the age of 21 days, when compared
to an age of 15 days, when only non-growing small follicles are
present. In situ hybridization has revealed that PACAP receptor
mRNA is present mainly in the granulosa cells of the large pre-
antral follicles, while atretic follicles and mural granulosa cells are
devoid of the receptor. The authors have also demonstrated that
the dominant splice variant of the PAC1 receptor was the short
variant in the ovary (Park et al., 2000). Gonadotropin stimula-
tion has been shown to induce PACAP receptor mRNA expression
in the granulosa cells of the preovulatory follicles (Ko and Park-
Sarge, 2000; Park et al., 2000). Pregnant mare serum gonadotropin
(PMSG), on the other hand, causes reduction of PACAP receptor
gene expression. PMSG induces multiple follicular growth to the
preovulatory stage. These observations suggest an involvement of
PACAP in the follicular growth, and in ovulation, in a stage- and
time-dependent manner. The observation that PACAP receptor
expression is restricted to granulosa cells of the growing follicles
at the time of puberty and to granulosa cells of preovulatory fol-
licles after gonadotropin treatment indicates that PACAP may act
in a limited time-window in the ovary. Progesterone receptors
have been shown to be involved in the induced PAC1 receptor
expression (Ko and Park-Sarge, 2000).
A more detailed analysis of the rat ovarian PACAP receptor
expression has confirmed the expression of PAC1 receptors in the
granulosa cells and, furthermore, the presence of VPAC2 receptors
in these cells (Vaccari et al., 2006). Theca cells do not express PAC1
receptors, only VPAC1 and 2 receptors. Fully developed oocytes
only express the PAC1 receptor. hCG stimulation has been found to
induce PAC1 receptor expression in granulosa andVPAC2 receptor
expression in theca cells. The VPAC receptor expression has been
found to have a lower expression level than the PAC1 receptor. This
study has also confirmed the previous findings of Park et al. (2000)
describing receptor expression at 3 days after birth with a marked
increase before puberty. In addition, they found that VPAC1 recep-
tors decreased with age and VPAC2 receptors remained constant.
Immunohistochemical analysis revealed the presence of VPAC1
receptors in association with stromal blood vessels in the vicinity
of the follicles, especially at the entrance site of the ovarian arter-
ies into the medulla. The expression of the VPAC2 receptors was
more ubiquitous in the ovary. Denuded oocytes express only the
PAC1 receptor, which could not be detected in Met-I and II phases
in oocytes matured in vivo. Gras et al. (2000) also described PAC1
and VPAC2 receptors in preovulatory follicles. All three types of
the PACAP receptors have been identified in human granulosa
cells, although the main receptor types in these cells seem to be the
VPAC receptors (Morelli et al., 2008).
All three receptors have also been identified in the mouse
(Barberi et al., 2007). PAC1 receptors could be stimulated by hCG,
VPAC2 only mildly stimulated, and VPAC1 downregulated. The
authors suggested that the contemporary induction of PACAP
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and PAC1 receptors by hCG in granulosa cells of preovulatory
follicles indicates an important role for PACAP around the time
of ovulation (Barberi et al., 2007).
ACTIONS OF PACAP IN THE OVARY
Follicular development, hormone production, and ovulation
In all mammalian species, the early stages of folliculogenesis,
including the initiation of primordial follicle growth, are inde-
pendent from gonadotropins (Latini et al., 2010). Fine balances
between inhibitory and stimulatory signals regulate follicular
recruitment. PACAP has been shown to inhibit primordial to pri-
mary follicle transition (Latini et al., 2010); PACAP did not influ-
ence granulosa cell viability at these stages but inhibited prolifera-
tion. PACAP also inhibited the growth of preantral follicles. These
observations indicate an important role of PACAP in follicular
recruitment (Latini et al., 2010). On the other hand, at later stages,
PACAP can prime immature follicles (Gras et al., 2005). A 12-
h PACAP priming stimulates FSH-induced estradiol production,
which is an important step in cyclic recruitment, when a cohort
of antral follicles escapes apoptosis and reaches the preovulatory
stage (Gras et al., 2005). These results show a fine balance between
factors, including PACAP, that play a role in follicular recruitment.
Other studies have also shown that PACAP plays an important
role in preantral follicular growth and differentiation (Cecconi
et al., 2004). In the mouse ovary, PACAP or VIP alone did not
affect follicular growth, but they both inhibited it when added to
FSH-stimulated follicles. Both peptides caused a dose-dependent
inhibition of follicle growth, antrum formation, granulosa cell
proliferation, and estradiol production (Cecconi et al., 2004).
Studies on the endocrine effects of PACAP revealed that PACAP
can stimulate cAMP accumulation and steroidogenesis in the rat
ovary (Zhong and Kasson, 1994; Heindel et al., 1996; Vaccari et al.,
2006). Granulosa cell cultures responded to PACAP treatment
with increased production of estrogen, progesterone, and 20alpha-
dihydroprogesterone. This effect was dose-dependent and more
potent than similar effects of VIP and GHRH (Zhong and Kasson,
1994). The peptide was also able to augment FSH-induced prog-
esterone and 20alpha-dihydroprogesterone accumulation, and in
high doses that of estrogen. The PACAP-stimulated progesterone
accumulation was minimal in the absence of androstendion and
dramatically augmented in the presence of the androgen. This
shows that androgens are required for the PACAP to stimulate
steroid production and indicate that PACAP might play a role in
modulating the production of steroids in the ovary (Zhong and
Kasson, 1994). The effects of PACAP depend on the presence of
LH. In cultured luteal cells of the rat,PACAP alone stimulates prog-
esterone, 20alpha hydroxyl-4-pregnene-3-one along with cAMP
accumulation (Usuki and Kotani, 2001, 2002). However, when
LH is present, PACAP in high concentrations inhibits the LH-
induced cAMP accumulation and progesterone production, while
it enhances the LH-induced stimulation of 20alpha hydroxyl-4-
pregnene-3-one production (Kotani et al., 1998). This decreases
the ratio of progesterone to 20alpha hydroxyl-4-pregnene-3-one
in LH-stimulated cells, which suggests an involvement in lute-
olysis. This is supported by the finding that PACAP suppresses
increases in LH receptors in luteal cells (Usuki and Kotani, 2001).
Gras et al. (2000) showed that PACAP can stimulate progesterone
production and cAMP synthesis, and the involvement of the PKA
pathway. These data together provide evidence for the involvement
of PACAP as an autocrine-paracrine regulator of ovarian hormone
production, especially in preovulatory follicles (Gras et al., 2000).
Interestingly, one intracerebroventricular PACAP treatment
was shown to inhibit ovulation in adult animals (Koves et al.,
1998). Injecting PACAP before the critical period of the proe-
strous stage, blocks the ovulation and prevents the proestrous LH
surge (Koves et al., 1996). Furthermore, neonatal administration
of PACAP delays onset of puberty in female animals (Szabo et al.,
2002).
The effects of PACAP on ovarian steroidogenesis have been con-
firmed in human studies as well (Apa et al., 1997), where PACAP
was found to stimulate progesterone synthesis without synergistic
effects with hCG. This was tested in corpora lutea obtained from
non-pregnant women undergoing hysterectomy.
PLC was activated by PACAP in granulosa but not theca cells
(Vaccari et al., 2006). Plasminogen activators are known to be
involved also in ovulation. PACAP has been shown to increase the
tissue-type plasminogen activator and to decrease the urokinase-
type one (Apa et al., 2002).VIP did not show this effect in granulosa
cells, but when entire follicles were exposed to the peptides, both
VIP and PACAP exerted similar stimulatory effects on tissue-type
plasminogen activator levels, supporting the observations of dif-
ferent PACAP/VIP receptors being expressed in different ovarian
compartments (Apa et al., 2002).
Apoptosis
In addition to gonadotropins, factors secreted from granulosa cells,
including steroids, growth factors, and cytokines, are essential for
granulosa cell survival and follicular growth (Matsuda et al., 2012).
Granulosa cells are the initial population to undergo apoptosis in
atretic follicles, indicating their role in the initiation of follicu-
lar atresia (Matsuda et al., 2012). Besides estradiol, as the main
ovarian steroid influencing follicular apoptosis, several other fac-
tors play an important role. Among those, insulin-like growth
factor, epidermal growth factor, fibroblast-like growth factor, and
interleukin-1 beta have prosurvival effects, while the Fas ligand
system and the tumor necrosis alpha are proapoptotic. Pro- and
antiapoptotic members of the mitochondrial Bcl family have also
been described to play an important role (Matsuda et al., 2012). A
few papers suggest that PACAP is also one of the factors influencing
granulosa cell death and survival.
One of the main effects of PACAP is its cell survival-promoting
effects, which was first described in neuronal cells, and thus,
PACAP was designated as an important neuroprotective peptide
(Vaudry et al., 2002; Somogyvari-Vigh and Reglodi, 2004). How-
ever, numerous studies have revealed that the antiapoptotic effects
of PACAP are not restricted to neuronal cells, but can be shown
in several other cell types, such as lymphocytes (Delgado and
Ganea, 2000), prostate cancer cells (Gutierrez-Canas et al., 2003),
endothelial cells (Racz et al., 2007), retinal pigment epithelial cells
(Fabian et al., 2012), and even in the invertebrate mollusks (Pirger
et al., 2008). Therefore, PACAP can be considered as a general cyto-
protective peptide. VIP, structurally the closest peptide to PACAP
has been described to have antiapoptotic effects in the ovary (Flaws
et al., 1995).
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Based on these data, it is expected that PACAP can also exert
antiapoptotic effects in ovarian cells. Indeed, several studies have
shown this in granulosa cells. In isolated granulosa cells, apoptosis
can be induced by serum-free culturing. In accordance with the
generally known antiapoptotic role of PACAP, the peptide could
reduce the granulosa cell apoptosis in a dose-dependent manner,
an effect that could be blocked by the PACAP antagonist PACAP6-
38 (Vaccari et al., 2006). These results are in accordance with ear-
lier observations showing that PACAP could block the apoptotic
cascade in granulosa cells (Lee et al., 1999) and that the LH sup-
pression of follicle apoptosis was partially blocked by PACAP 6-38.
The antiapoptotic effect of PACAP was also confirmed in human
granulosa-luteal cells (Morelli et al., 2008). Both PACAP and VIP
could reverse the decrease in procaspase-3 induced by the serum
withdrawal. However, it was found that spontaneous apoptosis
was not influenced by PACAP in another study (Gras et al., 2005).
Expression of PACAP in both benign and malignant ovarian
tumors has been shown (Odum and Fahrenkrug, 1998). Higher
levels were found in cancers than benign tumors. The authors
suggest a trophic function of PACAP in ovarian cells (Odum
and Fahrenkrug, 1998). Interestingly, PACAP does not influence
the cisplatin-induced toxicity in proliferating ovary cells of the
CHO ovarian cell line (Aubert et al., 2008). The same treatment,
however, does prevent toxicity and related apoptosis in cerebellar
granule cells. This dissociation in the antiapoptotic behavior of
PACAP could be of high clinical importance: PACAP can decrease
the cisplatin-induced neurotoxic side effects while leaving the
antitumor therapeutic effect intact (Aubert et al., 2008).
Effects in oocytes
Fully developed oocytes express PAC1 receptor and the addition
of nanomolar concentrations of PACAP induces calcium release.
However, this answer could not be observed in Met-I and II
phase oocytes, supporting that finding that receptors are expressed
stage-specifically (Vaccari et al., 2006).
In Xenopus oocytes, PACAP has been described to modu-
late membrane potential by eliciting hyperpolarization-activated
chloride current, thereby affecting oocyte physiology (Kato et al.,
1997).
Very interesting results have been described by Apa et al. (1997)
supporting both a direct and indirect effect of PACAP on oocyte
maturation. Mammalian oocytes are known to arrest in the first
meiotic division, which is resumed at the time of the preovulatory
LH surge. The inhibition of oocyte maturation and its relief is
mediated by gonadotropins in conjunct with several other factors,
while only a few are known to act directly on oocytes. The authors
described that PACAP accelerated meiotic maturation in follicle-
and cumulus-enclosed oocytes while inhibiting meiotic matura-
tion in denuded oocytes (Apa et al., 1997). This result was not due
to a direct cytotoxic effect because the inhibition on oocyte matu-
ration was reversible when PACAP was removed from the medium.
This difference in PACAP action on enclosed and denuded oocytes
support the stage-dependent regulatory effects of PACAP. Other
studies have also confirmed the effect of PACAP on the meiotic
processes. In the mouse ovary, Cecconi et al. (2004) found that
PACAP severely impaired meiotic maturation in oocytes isolated
from the follicles.
Recently, mass spectrometric and radioimmunoassay analy-
sis have shown that PACAP is present in human follicular fluid
obtained from patients undergoing hyperstimulation treatment
(Brubel et al., 2011; Koppan et al., 2012). PACAP could be iden-
tified in all human samples examined. Correlation was found
between retrieved oocytes and PACAP levels in the follicular fluid
drawing the attention to PACAP as an important factor in the
medium of the developing oocyte and its possible future use as a
biomarker in women with fertility problems (Koppan et al., 2012).
EVOLUTIONARY PERSPECTIVES
Recent reports point to the important roles of PACAP in fish
reproduction, pointing to the fact that the effects of PACAP on
the hypothalamo-pituitary axis, as well as in the gonads, are con-
served and biologically ancient functions (Levy and Degani, 2011,
2012). In fish, stage-specific expression of PACAP has also been
revealed. For example, higher PACAP expression can be found in
female blue gourami, with oocytes in the final maturation stage,
than in vitellogenic individuals. Also, higher expression was found
in mature males that are not reproductively active than in nest
builders and juveniles (Levy and Degani, 2012). PACAP is thus,
differentially expressed in females and males. PACAP acts in close
association with GnRH in fish reproduction and the expression
and actions of PACAP also depend on environmental factors, such
as temperature (Levy et al., 2011; Levy and Degani, 2012). It has
been proposed that PACAP is involved in the final oocyte matu-
ration in females and in males it is mainly associated with sexual
behavior (Levy et al., 2010). In the zebrafish, a new type of PACAP
has been described in the ovary and its role as an ovarian factor
mediating gonadotropin action have been suggested (Wang et al.,
2003).
ROLE OF ENDOGENOUS PACAP
Given the important functions of PACAP in reproduction out-
lined above, it would be expected that the lack of endogenous
PACAP have major effects on fertility and reproduction. Indeed,
PACAP deficient mice have been shown to have lower reproduc-
tive rates in several studies (Shintani et al., 2002; Sherwood et al.,
2007; Isaac and Sherwood, 2008). To study the exact mechanism,
a few studies examined the possible background for this lower
reproductive rate. Interestingly, Isaac and Sherwood (2008) found
that these mice had normal puberty onset, estrous cycle, and sem-
inal plugs when paired with males. However, the birth rate after
mating was only 20% when compared to the 100% in wild type
mice. The authors found no defect in ovulation, ovarian histol-
ogy, or fertilization, but they found major defects in implantation
and associated hormone levels (Isaac and Sherwood, 2008). Simi-
larly, low birth rates were found by Shintani et al. (2002), but they
also found reduced mating and maternal behaviors. It is possi-
ble that in the ovary, compensatory mechanisms counteract the
lack of PACAP and thus, no major alterations can be detected
under normal circumstances. However, more studies are neces-
sary to elucidate the exact role of endogenous PACAP in the
ovary. Furthermore, in several other organs, including intestine,
kidney, retina, and central nervous system, PACAP deficient mice
do not exhibit major alterations unchallenged conditions (Reglodi
et al., 2012). However, in case of stressors or under pathological
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conditions, PACAP deficient mice react with increased vulnerabil-
ity and the observed deficits have been shown to be more severe
in mice lacking endogenous PACAP (Reglodi et al., 2012). Based
on these observations, it is possible that endogenous PACAP has
ovarian functions not compensated under challenged or patho-
logical conditions. Further studies are required to shed light on
this possibility.
CONCLUDING REMARKS
The present review summarized findings on the presence and
effects of PACAP in the ovary. It has to be emphasized that this
is only one role in the plethora of actions that PACAP plays
in fertility and reproduction and that the detailed discussion of
these is beyond the scope of the present review. Briefly, PACAP,
at the hypothalamic level, influences receptive behavior in female
rodents, in association with GnRH and steroids (Apostolakis et al.,
2004, 2005), and plays an important modulatory role in pituitary
hormone production. The role of PACAP in the hypothalamo-
pituitary-gonadal axis has been reviewed several times previously
(Rawlings and Hezareh, 1996; Nussdorfer and Malendowicz, 1998;
Sherwood et al., 2000; Koves et al., 2003;Vaudry et al., 2006; Counis
et al., 2007).
Pituitary adenylate cyclase activating polypeptide also plays a
role in the muscle contraction of the vaginal wall as well as that of
the uterus and uterine tube (Steenstrup et al., 1995; Ziessen et al.,
2002), and even decreased immunoreactivity has been shown in
premenopausal and postmenopausal women in the vaginal wall
(Hong et al., 2008). The PACAPergic innervation of the female
genital tract has also been shown and has been associated with
nerves originating from the paracervical ganglia (Fahrenkrug and
Hannibal, 1996; Fahrenkrug et al., 1996).
Effects of PACAP have also been shown in the placenta where
PACAP and its receptors are present (Scaldaferri et al., 2000; Koh
et al., 2005; Brubel et al., 2010), where the peptide influences blood
flow in the utero-placental unit (Steenstrup et al., 1996) and influ-
ences survival of trophoblast cells (Boronkai et al., 2009). The
serum level of PACAP increases in the third trimester of pregnancy
in healthy pregnant women and it markedly decreases during
delivery, reaching prebirth levels 3 days after delivery (Reglodi
et al., 2010). High concentrations of PACAP have been shown
in human and animal milk (Borzsei et al., 2009; Csanaky et al.,
2012), which suggests that the peptide is also an important nutri-
tional source for the newborn. However, its exact function in
breastfeeding has not been identified yet.
In summary, PACAP is one of the peptides regulating germ
cell development in the ovary and it has several other regulatory
functions in reproduction. PACAP influences ovarian hormone
production, affects meiosis, and is an important local regula-
tor of follicular development. The exact physiological role and
its possible clinical importance still awaits further investigation,
but the current evidence points to a possible clinical diagnostic
or therapeutic use of the peptide in both human and veterinary
fertility.
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